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Abstract
 
Survival of antigen-experienced T cells is essential for the generation of adaptive immune
 
responses. Here, we show that the genetic and antibody-mediated inactivation of CD152
 
(cytotoxic T lymphocyte antigen 4) in T helper (Th) effector cells reduced the frequency of
nonapoptotic cells in a completely Fas/Fas ligand (FasL)–dependent manner. CD152 cross-
 
linking together with stimulation of CD3 and CD28 on activated Th2 cells prevented activation-
induced cell death (AICD) as a result of reduced Fas and FasL expression. Apoptosis protection
conferred by CD152 correlated with the up-regulation of Bcl-2 and was mediated by phos-
phatidylinositol 3 kinase, which prevented FasL expression through the inhibitory phosphory-
lation of Forkhead transcription factor FKHRL1. We show that signals induced by CD152 act
directly on activated T lymphocytes and, due to its differential surface expression on activated
Th1 and Th2 cells, induce resistance to AICD mainly in Th2 cells.
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Introduction
 
The decision between survival and apoptosis of T cells is of
particular importance for adaptive immune responses to
ensure that a defined number of specialized T cells remain
in the organism, thus maintaining homeostasis and memory.
The primary form of apoptosis of clonally expanded T cells
is activation-induced cell death (AICD), mainly controlled
by the Fas (CD95) system (1, 2). Fas-mediated AICD is
considered to be the primary mechanism in the deletion of
mature CD4 T cells in the periphery.
 
In the absence of appropriate costimulation, TCR signaling
induces Fas and Fas ligand (FasL) expression (3). Ligation of
Fas initiates the recruitment of Fas-associated death domain
and caspase-8 that triggers the proteolytic caspase cascade,
resulting in the cleavage of various proteins and apoptosis
(4). Several mechanisms exist to stop death processes either
at the receptor, mitochondrial, or caspase level. Survival
mechanisms are also mediated by phosphatidylinositol 3 kinase
 
(PI3
 
 
 
K), which activates protein kinase B/Akt, an antiapop-
totic kinase that inactivates proapoptotic molecules such as
Bad and Forkhead transcription factor FKHRL1 (5, 6).
CD28 costimulatory signaling and cytokines have been
 
suggested to up-regulate the antiapoptotic molecules Bcl-x
 
L
 
and c-FLIP during an immune response (7–9). Importantly,
some effector T cells survive and contribute to long-term
memory (10).
Cytotoxic T lymphocyte antigen 4 (CTLA-4, CD152) is
a major down-regulator of immune responses (11–13). In
most circumstances, the two homologues CD28 and
CD152, which share common ligands, fulfill opposing
functions during T cell activation. Triggering of CD28
strongly up-regulates IL-2 production and T cell proliferation,
which is counterregulated by CD152-mediated inhibition
of IL-2 transcription and cell cycle progression (14).
CD28 also leads to the stabilization of IL-2 mRNA and up-
regulation of Bcl-x
 
L
 
, events that are not counterregulated by
CD152 (15). The underlying mechanisms responsible for
these effects are unclear. CD28 has been reported to bind
 
to PI3
 
 
 
K, the adapters Grb-2/GADS, and the phosphatase
PP2A, whereas CD152 binds to PI3
 
 
 
K and the phos-
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phatases PP2A and SHP-2 (16–19). The coupling of CD28
and CD152 to different signaling mediators might indicate
that CD152 does not simply counteract CD28-mediated
costimulation.
During suboptimal activation of the T cell, CD152 en-
gagement leads to impaired T cell activation and to G1 cell
cycle arrest by inhibition of cyclin D3, CDK4, and CDK6
production (11–14, 20). Although CD28 and CD152 bind
to the same ligands, B7.2 and B7.1, on APCs, CD152
binds with a 20–50-fold higher affinity. CD28 is constitu-
tively expressed on CD4
 
 
 
 T cells, whereas CD152 is in-
ducible reaching maximal surface levels 48 h after T cell
stimulation (21). CD152 is transported from intracellular
vesicles to the cell membrane, where it is expressed at the
immunological synapse (22). This restricted regulation of
CD152 trafficking and localization represents a major con-
trol point for its inhibitory function. It has been proposed
that CD152 prevents some T cell clones with a high-affin-
ity TCR by decreasing their competitive advantage over
clones with a low-affinity TCR (22). Suggestive evidence
and correlations have also shown that CD152 ligation in
previously activated ConA blasts or 
 
 
 
CD3-stimulated T
cells might induce apoptosis to terminate the T cell re-
sponse (23, 24).
After initial activation, naive CD4
 
 
 
 cells differentiate
into Th1 and Th2 cells that secrete different cytokines. In-
terestingly, Th2 cells are substantially more resistant to
AICD than Th1 cells (25, 26). Whether the expression of
Fas or other apoptotic regulators is involved in this differ-
ential sensitivity after antigenic restimulation is controver-
sial (27). Although Fas-mediated apoptosis is functional in
CD152
 
 
 
/
 
 
 
 T cells in vivo (28), the role of CD152 in
AICD of activated primary T cells that are prone to AICD
remains unknown. Suggestive stainings for surface CD152,
which were, however, only performed in long-term T cell
clones, indicate that surface expression of CD152 might be
present in Th2 rather than in Th1 cell clones (29). CD152
has also been proposed as an inhibitor of Th2 cell differen-
tiation (30, 31). Owing to its low surface expression, detec-
tion of surface CD152 on primary T cells by conventional
techniques has been difficult. Therefore, the role of CD152
in the response of differentiated primary Th1 and Th2 cells
is almost entirely unknown.
Here, we investigated the functional role of CD152 on
individual primary Th1 and Th2 cells using a novel sensi-
tive immunofluorescent labeling technique. We show for
the first time that, after antigenic restimulation, CD152
surface expression is induced at high frequencies in Th2
cells compared with Th1 cells. Interestingly, CD152 ren-
dered activated T cells resistant to AICD, whereas inhibi-
tion of CD152 sensitized cells for apoptosis. We identified
that apoptosis protection by CD152 was dependent on the
suppression of the Fas system and mediated by PI3
 
 
 
K,
which induced the up-regulation of Bcl-2 and the inactiva-
tion of FKHRL1, a transcription factor regulating FasL ex-
pression. Thus, CD152 regulates AICD by targeting PI3
 
 
 
K
and, due to higher frequencies of CD152 surface expres-
 
sion in Th2 than in Th1 populations, induces resistance to
AICD mainly in Th2 cells. This novel activity of CD152
could explain the resistance of Th2 cells to apoptosis and
might be important for T cell homeostasis.
 
Materials and Methods
 
Mice.
 
Mice transgenic (tg) for the DO11.10 
 
 
 
/
 
 
 
-TCR
(OVA-specific TCR
 
tg/tg
 
) on a BALB/c background (a gift from
D.Y. Loh, Washington University School of Medicine, St. Louis,
MO), CD152 knockout mice on a C57/B6 background (a gift
from J.P. Allison, University of California at Berkeley, Berkeley,
CA), and C57/B6 and BALB/c mice were bred under pathogen-
free conditions in the animal facility of the Bundesgesundheitsamt
in Berlin and used at the age of 5–7 wk. Offspring of CD152
 
 
 
/
 
 
 
mice were used at the age of 3 wk and genotyped by PCR using
the following oligonucleotide primers: CD152, 5
 
 
 
-TGGAGTC-
CTTCATAGTTAGG-3
 
 
 
 and 5
 
 
 
-GCAAGATGGTGAGTGT-
GATGTT-3
 
 
 
; and Neo, 5
 
 
 
-CATAGTTAGGTCTGTGAT-
GC-3
 
 
 
 and 5
 
 
 
-CGTCAAGAAGGCGATAGAAGGC-3
 
 
 
.
 
Antibodies, Cytokines, and Reagents.
 
The following antibod-
ies against murine antigens were used: 
 
 
 
CD152 (UC10–4F10–
11; Becton Dickinson), 
 
 
 
CD25 (BD Biosciences), 
 
 
 
TCR
 
tg
 
(KJ1–26.1), 
 
 
 
FasL (MFL3; BD Biosciences), and 
 
 
 
Fas (Jo2; BD
Biosciences) in their respective forms of FITC, PE, and Cy5 con-
jugates. 
 
 
 
CD28 (37.51), 
 
 
 
CD3 (145–2C11), 
 
 
 
CD4 (GK-1.5/4),
 
 
 
CD8 (196), 
 
 
 
CD62L (MEL-14), 
 
 
 
CD152 (UC10–4F10–11),
control antibodies (560–31.1B9; provided by J.P. Allison), 
 
 
 
IL-
12 (C17–8.6), and 
 
 
 
IFN-
 
 
 
 (AN18.17.24) were purified from hy-
bridoma supernatants with protein G and controlled by HPLC
and FACS
 
®
 
 analysis. 
 
 
 
CD152 Fab fragments were prepared with
the Immunopure Fab preparation kit (Pierce Chemical Co.). The
fragments were controlled by HPLC and by Ag-specific T cell
stimulations. The 
 
 
 
FasL Ab (3C82; BioCheck) was used at a
concentration of 20 
 
 
 
g/ml in neutralization experiments. Con-
trol antibodies such as IgG1 (R3–34), FITC-conjugated ham
IgG2 (
 
 
 
KLH, HA4/8), PE-conjugated ham IgG, and annexin-
V–PE conjugates as well as 
 
 
 
IL-2 (JES-61A12) and 
 
 
 
IL2R
 
 
 
(3C7) that were used at 20 
 
 
 
g/ml were obtained from BD Bio-
sciences. Recombinant IL-12 was purchased from R&D Systems
and used at 10 ng/ml. IL-4 (supernatant of myeloid cell line
P3X63 Ag.8.653 transfected with murine IL-4 cDNA) was added
at an equivalent of 30 ng/ml to the cultures. IL-2 was purified
from supernatants of X63.IL-2.6 cells. IL-2 and IFN-
 
 
 
 were de-
tected in culture supernatants by ELISAs (R&D Systems) with a
detection limit of 2 pg/ml. Dibutyryl cAMP (dB-cAMP), forsko-
lin, wortmannin, and LY294002 were obtained from Sigma-Aldrich
and used at 0.5 mM and 60, 1, and 30 
 
 
 
M, respectively. L-mimo-
sine (ICN Biomedicals) was used at 60 
 
 
 
g/ml. Magnetic micro-
beads 
 
 
 
CD4, 
 
 
 
CD62L, 
 
 
 
CD90, and 
 
 
 
FITC multisort microbeads
were purchased from Miltenyi Biotech. Sulfate polystyrene latex
microspheres of 5 
 
 
 
m 
 
 
 
 0.1 
 
 
 
m diameter were obtained from
Interfacial Dynamics.
 
Cell Isolation.
 
Isolation of naive CD62L
 
high
 
CD4
 
 
 
 T cells from
OVA-specific TCR
 
tg/tg
 
 mice was performed using two-parameter
high-gradient magnetic cell separation (MACS) according to the
manufacturer’s instructions. CD4
 
 
 
 cells were isolated by positive
selection on an AUTOMACS system to a purity of 
 
 
 
99.3%, and
CD62L
 
high
 
 CD4
 
 
 
 cells were positively selected on AUTOMACS
to a purity of 
 
 
 
99% as determined by flow cytometry. Isolated
cells were stimulated with 1 
 
 
 
g/ml OVA
 
323–339
 
 peptide (Neosys-
tem) and APCs (2 
 
 
 
 10
 
6
 
 cells/ml) in RPMI 1640 medium con- 
Pandiyan et al.
 
833
 
taining 10% fetal calf serum, 0.3 mg/ml glutamine, and 10 
 
 
 
M
2-mercaptoethanol. CD90
 
 
 
 cell–depleted splenocytes from syn-
geneic BALB/c mice were used as APCs (1.5 
 
 
 
 10
 
6
 
 cells/ml).
 
Differentiation of Primary Th1 and Th2 Cells.
 
Naive (CD4
 
 
 
CD62L
 
 
 
)
CD4 cells were differentiated in a primary stimulation into Th1
or Th2 cells in the presence of OVA
 
323–339
 
 and T cell–depleted
splenocytes as APCs. For Th1 polarization, IL-12 and 
 
 
 
IL-4
were added to the cultures and for Th2 polarization, IL-4, 
 
 
 
IL-
12, and 
 
 
 
IFN-
 
 
 
 were used during a primary stimulation period
of 6 d. Cultures were split on day 3 after the onset of the primary
stimulation. Dead cells were removed by Ficoll gradient centrifu-
gation on day 6. Restimulation (secondary stimulation) was per-
formed with OVA
 
323–339
 
 and APCs. Polarities of Th1 and Th2
cells were routinely checked 3 d after the secondary Ag stimula-
tion by mitogen stimulation with PMA/ionomycin for 6 h and
incubation with brefeldin A for the last 2 h. To this end, intracel-
lular IFN-
 
 
 
 and IL-4 were stained in fixed (2% formaldehyde)
and permeabilized (0.5% saponin) cells and analyzed by FACS
 
®
 
.
 
Cell Stimulation.
 
CD4 T cells (10
 
6
 
 cells/ml) were stimulated
at a ratio of 1:1 with Ab-coupled microspheres. Cross-linking of
CD152 on CD4 cells was performed using latex microspheres
coated with antibodies as described previously (14). In brief, 10
 
7
 
microspheres/ml were suspended in PBS with 0.1 
 
 
 
g/ml 
 
 
 
CD3,
2 
 
 
 
g/ml 
 
 
 
CD28, 
 
 
 
CD152, or a hamster control Ab (NF18, 2.9
 
 
 
g/ml) and incubated for 1.5 h at 37
 
 
 
C, followed by washing
with PBS and blocking with 10% fetal calf serum. In some experi-
ments, 10
 
7
 
 microspheres/ml were suspended in PBS with 0.5 
 
 
 
g/
ml 
 
 
 
CD3, 1 
 
 g/ml  CD28,  CD152, or a hamster control Ab
(NF18, 4.5  g/ml). In case of CD152 cross-linking in the pres-
ence of inhibitors, secondary Th2 cells restimulated with Ag and
APCs for 48 h were used. After removal of dead cells, Th2 cells
were sorted for CD4 expression and replated with Ab-coated mi-
crospheres with or without CD152 cross-linking in the presence
of 50 U/ml IL-2 and the cell cycle inhibitors L-mimosine or dB-
cAMP. IL-2 was added during replating to avoid apoptosis caused
by growth factor deprivation or the addition of L-mimosine
alone. For inhibition of PI3 K, Th2 cells were restimulated with
plate-bound antibodies (2  g/ml of each  CD3 and  CD28) for
48 h. Cells were pretreated with wortmannin, LY294002, or ve-
hicle controls for 30 min before they were replated with micro-
spheres coated with 0.5  g/ml  CD3, 1  g/ml  CD28, 4.5  g/
ml  CD152, or control antibodies in the presence of IL-2. For
analyses of cells from CD152 /  mice, splenocytes were stimu-
lated with 1.5  g/ml Con A. After removal of dead cells,
CD152 /  cells were restimulated with 2  g/ml  CD3 and T
cell–depleted APCs from syngeneic CD152 /  mice.
Measurement of Cell Cycling and Apoptosis. Cell cycle progres-
sion was measured by labeling 107 cells/ml T cells with 10  M
5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE; Mo-
lecular Probes) in PBS/0.1% BSA for 6 min at room temperature.
The reaction was stopped by resuspending the cells in RPMI 1640
medium. To measure cell death, cells were stained with annexin-
V–PE and propidium iodide (PI) according to the manufacturer’s
instructions to exclude early apoptotic and late apoptotic/dead
cells, respectively. The frequency of nonapoptotic cells was taken
into consideration for all experiments. Routinely, staining was
controlled by calcium chelation with 2 mM EGTA. Apoptotic
DNA fragmentation was measured by TdT-mediated dUTP nick-
end labeling (TUNEL) staining using the FLOWTACS kit (R&D
Systems). For measurement of caspase activation, cells were incu-
bated for 20 min with the permeable substrate FITC-VAD-fmk
(CaspACE; Promega) at a final concentration of 5  M, followed
by subsequent flow cytometric analysis.
Four-color Cytometric Analysis of Bcl-2 and CD152 Surface Ex-
pression. Surface expression of CD152 was detected using mag-
netofluorescent liposomes (32). T cells were incubated with un-
conjugated hamster  CD152 Ab at 1  g/ml for 15 min at 4 C.
Cells were washed twice, incubated with Cy5 dye-filled lipo-
somes, and conjugated to  ham Fab fragments for 30 min at
4 C. Unbound liposomes were removed by washing the cells
twice with PBS-BSA. The specificity of CD152 staining was
controlled by isotype control Ab conjugated with Cy5-filled
liposomes as well as by incubation of cells with Cy5-filled lipo-
somes only. The expression of Bcl-2 was detected using a Cyto-
fix/Cytoperm staining kit obtained from BD Biosciences
(3F11-PE). Cytometric analyses were performed using a FACS-
calibur™ (Becton Dickinson) and CellQuest™ software. Dead
cells were excluded by forward and side scatter gating and PI
staining in surface staining analyses.
Immunoblotting. Phosphorylation-induced inactivation of Fork-
head transcription factor FKHRL1 was detected by immunoblot
analysis as described previously (33). In brief, Th2 cells were cul-
tured under the indicated conditions in the presence and absence
of CD152 ligation and lysed after 24 h in sample buffer. Proteins
(25  g/lane) were separated on a SDS–polyacrylamide gel and
electroblotted onto a polyvinylidene difluoride membrane.
Membranes were blocked for 1 h with 5% milk powder in TBS
containing 50 mM NaF and immunoblotted for 1 h with a phos-
phorylation-specific polyclonal Ab recognizing phosphorylated
Thr-32 of FKHRL1 (Santa Cruz Biotechnology, Inc.). Specific-
ity of the Ab was controlled by incubation of the Ab with a
FKHRL1 peptide before immunoblotting. Membranes were
washed four times with TBS/0.02% Triton X-100 and incubated
with a peroxidase-conjugated goat anti–rabbit Ab for 1 h. After
extensive washing, the reaction was developed by enhanced
chemiluminescent staining.
Results
CD152 Is Predominantly Expressed on the Surface of Th2
Cells. CD152 is not expressed on the surface of resting T
cells and difficult to detect even after stimulation of T cells
(22, 24, 34, 35). To analyze CD152 expression in different Th
populations, we stimulated naive (CD4 CD62L ) OVA-
specific CD4  T cells in a primary stimulation with the
peptide OVA323–339 and congenic APCs using Th1 and
Th2 culture conditions, respectively. On day 6, cells were
restimulated with congenic APCs and Ag. Polarization of
primary Th1 and Th2 cells resulted in a purity of  99.5%
in both effector populations, as assessed by determining
IFN-  producers in the Th2 and IL-4 producers in the
Th1 population after stimulation with PMA and ionomy-
cin on day 3 of a secondary Ag-specific stimulation (Fig. 1
A). To unambiguously identify T cells expressing surface
CD152, we used a staining technique based on CD152-
specific immunofluorescent liposomes, which increased the
detection sensitivity at least 1,000-fold (32). Expression of
surface CD152 was evaluated at various time points after
primary activation of naive T cells in Th1 or Th2 condi-
tions and a subsequent secondary Ag stimulation (Fig. 1, B
and C). Specific surface expression of CD152 was detected
with similar frequencies in primary Th1 and Th2 cultures
after primary stimulation and peaked after 48 h. Thereafter,CD152 Signaling Induces Resistance to Apoptosis 834
the frequency of surface CD152-expressing cells declined
in Th2 cultures until day 5, whereas surface CD152-express-
ing Th1 cells were hardly detectable (1%) 3 d after stimula-
tion. After secondary stimulation,  40% of the Th2 cells
expressed CD152 and only  10% of the Th1 cells dis-
played CD152 on their surface 48 h after restimulation
(Fig. 1, B and C). Thus, both primary Th1 and Th2 cells
are able to express surface CD152, but CD152 is expressed
at a four- to fivefold higher frequency in Th2 cells, indicat-
ing that CD152 might play a more prominent role in Th2
than in Th1 cells.
Inactivation of CD152 Induces Susceptibility to AICD Mainly
in Th2 Cells. To examine the role of CD152 during
AICD, serological inactivation of CD152 was performed
by adding neutralizing  CD152 Fab fragments to Th1 and
Th2 cells during primary and secondary stimulations. Non-
apoptotic cells were evaluated after different times after re-
stimulation using double staining with PI and annexin-V.
PI was used to identify dead and late apoptotic cells. An-
nexin-V stains phosphatidylserine in a Ca2 -dependent
way, which is exposed at early stages of apoptosis. The
specificity of the staining was controlled by chelating Ca2 
with EGTA demonstrating no unspecific annexin-V stain-
ing (unpublished data). After restimulation of Ag-experi-
enced cells for 6 d, only 36% of the Th1 cells remained vi-
able, whereas 57% of the Th2 cells survived after the onset
of secondary Ag stimulation (Fig. 2 A). Serological block-
ade of CD152 by  CD152 Fab fragments led to reduced
frequencies of surviving cells and, interestingly, only low
numbers of Th1 (22%) and Th2 cells (29%) remained via-
ble (Fig. 2 A). The small difference in cell survival of
5–10% between activated, CD152-blocked Th1 and Th2
cells was highly reproducible. In principle, similar effects of
CD152 in Th1 and Th2 cells were found after 3 d of re-
stimulation, although cell death was clearly less pronounced
at this earlier time point (Fig. 2 A). A survival-promoting
effect of CD152 was confirmed when cell death was ana-
lyzed by measurement of DNA fragmentation using
TUNEL staining or by the flow cytometric detection of
caspase activation (Fig. 2, B and C). Thus, CD152 block-
ade enhanced the susceptibility to apoptosis in differenti-
ated Th cells, which was more pronounced in Th2 cells
compared with Th1 cells.
We further used cells from mice harboring a genetic in-
activation of CD152. After polyclonal stimulation of sple-
nocytes with ConA, substantially more CD152 /  spleno-
cytes were killed on day 5 compared with wild-type cells
(Fig. 3 A). Excluding early apoptotic (annexin-V , PI )
and dead (PI ) T cells,  30% more of the wild-type cells
than CD152 /  cells remained viable. A comparable differ-
ence between CD152 /  and CD152-expressing cells was
found, when dead cells were removed and CD4  T cells
were restimulated with  CD3 for a further 48 h (Fig. 3 B).
Enhanced apoptosis of CD152 /  cells was also confirmed
by TUNEL staining (Fig. 3 C). Thus, although it must be
considered that CD152 /  cells differ even after activation
from wild-type cells, in the presence of functional CD152,
less apoptosis occurred after primary and secondary cell
Figure 1. Detection of CD152 surface ex-
pression on Th1 and Th2 cells by enhanced
fluorescence liposome staining. (A) Polariza-
tion of Th1 and Th2 cells. CD4 CD62L 
OVA-specific TCRtg/tg T cells were stimulated
with 1  g/ml OVA323–339 and T cell–depleted
splenocytes. Th cell polarization was routinely
determined by intracellular FACS® staining
for IFN-  and IL-4 on day 3 after the onset
of an Ag-specific restimulation using PMA/
ionomycin stimulation for 6 h (see Materials
and Methods). Stainings with isotype-matched
control antibodies are shown (left). (B) CD152
surface expression in differentiating and estab-
lished Th1 and Th2 cells. The percentage of
surface CD152-expressing CD4  cells was
detected by staining with an  CD152 Ab and
 hamIgG-specific liposomes. Cell analysis was
performed at different time points after a pri-
mary Ag-specific stimulation of naive T cells
in their Th1 or Th2 milieu as indicated, followed
by a secondary Ag stimulation of the estab-
lished Th1 and Th2 cells. The specificity of
the stainings was controlled with isotype-
matched control antibodies. Indicated frequencies
are values subtracted from background staining
ranging from 0.5 to 2%. Surface CD152 
TCRneg cells are CD19  B cells (analysis not
depicted). (C) Representative data of CD152
staining with the enhanced liposome FACS®
technique showing surface CD152  cells 48 h
after secondary stimulation. The indicated values show the frequencies of surface CD152 -expressing cells among all TCRtg CD4  cells. Stainings
with isotype-matched control antibodies are shown (left). One out of five similar experiments is shown.Pandiyan et al. 835
stimulation, which supports the idea that CD152 could be
involved in apoptosis resistance.
CD152-induced Apoptosis Resistance in Preactivated T Cells
Is Independent of IFN-  and IL-2. Because CD152 block-
ade may lead to enhanced IFN-  production (35), which
has been implicated in AICD (36), IFN-  levels were ana-
lyzed in the cultures using a sensitive ELISA. After serolog-
ical inactivation of CD152, enhanced IFN-  production
was detectable in supernatants of Th1 but not Th2 popula-
tions (Fig. 4 A). Thus, at least in Th2 cells, enhanced
IFN-  production was unlikely to be responsible for the
reduced survival in the absence of CD152 engagement.
Blockade of CD152 during antigenic stimulation of pri-
mary T cells also enhances IL-2 synthesis, which could af-
fect apoptosis induction (26, 37, 38). After neutralization of
CD152 with Fab fragments, we found enhanced IL-2 lev-
els in supernatants of Th1 cells, but also Th2 cells, increas-
ing from 0.01 to 2 ng/ml (unpublished data). The en-
Figure 2. Th1 cells are more
sensitive to AICD than Th2
cells, and genetic or serological
blockade of CD152 further en-
hances apoptosis sensitivity. (A)
AICD in Th1 and Th2 cells and
the effect of CD152 inhibition.
CD4 CD62L  TCRtg/tg spleno-
cytes were stimulated with
OVA323–339 and T cell–depleted
APCs for 1 wk under their re-
spective Th1 or Th2 culture
conditions. Polarized Th1 and
Th2 cells were restimulated in
the presence of 200  g/ml of
neutralizing   CD152 Fab or
hamster control Fab fragments.
3 and 6 d later, cultures were
stained with annexin-V and PI
to detect early apoptotic cells
and late apoptotic/dead cells,
respectively. The data shown
represent one out of three similar
experiments. Stainings were also
performed on day 4 or 5 after
restimulation with similar results
(not depicted). Gatings in forward
scatter versus side scatter dot plots
are depicted (top). (B and C)
Effect of CD152 blockade on
apoptotic DNA fragmentation
and caspase activation. Th1 and
Th2 cells were stimulated and
restimulated in the presence of
 CD152 Fab or hamster control Fab fragments as described in A. On day 5, DNA fragmentation (B) was measured by TUNEL staining and caspase
activation (C) by labeling of cells with the fluorogenic caspase substrate FITC-VAD-fmk, followed by flow cytometric analysis. The data represent
the results from one out of two similar experiments. Similar results were obtained from stainings on day 6 after restimulation (not depicted).
Figure 3. CD152    T cells are more susceptible to AICD. Splenocytes from CD152 /  and CD152 /  mice were stimulated with 1.5  g/ml ConA.
Annexin-V/PI stainings were performed 96 h after the onset of a primary stimulation (A) or after restimulation with 2  g/ml  CD3, which was per-
formed after removal of dead cells for a further 48 h (B). The frequency of viable cells is indicated together with an annexin-V staining control performed
in the presence of EGTA (left). (C) Increased AICD in CD152 /  T cells compared with WT cells was also observed when apoptosis was measured by
TUNEL staining after primary and secondary stimulation with ConA and  CD3, respectively.CD152 Signaling Induces Resistance to Apoptosis 836
hanced apoptosis in CD152-blocked Th2 cells was not
reversed by inhibition of IL-2 signaling (Fig. 4 B). Further-
more, addition of exogenous IL-2 even slightly enhanced
survival of Th1 and Th2 cells (Fig. 4 C), but the CD152
effect was still clearly detectable, which indicated that the
susceptibility to apoptosis conferred by CD152 blockade
was not due to effects of IL-2.
CD152 Induces Resistance in Activated Th2 Cells Indepen-
dently of Cell Cycle Arrest. In the next experiments, we
asked whether CD152-mediated protection against AICD
was a consequence of altered cell cycle progression or a di-
rect effect of CD152. Because CD152 exerts its main func-
tion at its peak expression, we monitored its effect on an
equally activated CD4 T cell population 48 h after the onset
of cell stimulation. To avoid potential effects of IFN-  on
AICD (36), we focused on Th2 cells and induced AICD in
the presence of IL-2 as described previously (8). Th2 cells
were restimulated for 48 h with congenic APCs and OVA,
and Ab-coupled microspheres were used to cross-link
CD152 in combination with CD3 and CD28 coligation.
Individual nonapoptotic cells were determined 3 d (Fig. 5,
top) and 4 d later (not depicted) with similar results. 21%
more Th2 cells remained resistant to AICD after stimulation
with  CD3,  CD28, and  CD152 compared with CD3/
CD28-stimulated T cells. Thus, CD152 engagement of
Th2 cells triggered enhanced resistance to AICD, which
was even observed in the presence of  CD28.
Another hallmark of CD152 signaling is the induction of
G1 cell cycle arrest in lymphocytes (14). Because cell cycle ar-
rest might induce resistance to apoptosis (39), we performed
similar experiments in the presence of L-mimosine or dB-
cAMP, two drugs inducing G1 arrest (Fig. 5). As reported
previously (40), measurement of CFSE staining revealed that
both drugs arrested cell cycle progression (unpublished data),
and further analysis was only performed in nonproliferating
cells. In the presence of IL-2, L-mimosine and dB-cAMP
caused a moderate increase in the viability of cells that had
been restimulated solely with  CD3 and  CD28. Neverthe-
less, CD152 ligation induced a comparable increase in resis-
tance against AICD ( 20%), regardless of whether mimosine
or dB-cAMP was used. Replating of the L-mimosine–treated
cells without IL-2 caused dramatic cell death that could not
be analyzed. CD152 ligation of dB-cAMP–treated cells was
protective also without IL-2, although to a lesser extent than
in the presence of IL-2 (unpublished data). Thus, CD152-
induced resistance of Th2 cells against apoptosis was not
caused indirectly by reduced IL-2 production or G1 arrest,
but rather by a direct CD152 effect.
CD152 Regulates Apoptosis in a Fas/FasL-dependent Man-
ner. Because AICD is mainly mediated by the Fas system,
we investigated whether CD152 interfered with Fas/FasL
interaction. Th1 and Th2 effectors were generated under
our standard conditions by stimulation of naive T cells with
Ag plus APCs in the presence or absence of neutralizing
 CD152 Fab fragments. Upon Ag-specific restimulation,
Fas/FasL interaction was blocked with the FasL-specific Ab
3C82. Ag-stimulated Th1 cells showed only a 14% increase
in the number of cells undergoing AICD after CD152 in-
hibition, whereas the blockage of CD152 in Th2 cells re-
sulted in  30% more cell death 6 d after restimulation (Fig.
6 A). Analysis on day 5 gave similar results (unpublished
data). Prevention of Fas signaling by  FasL reversed the
sensitizing effect induced by CD152 blockade completely,
and also substantially inhibited AICD. Despite different fre-
quencies of Th1 and Th2 cells undergoing AICD, in both
populations the CD152-mediated effect was dependent on
the Fas/FasL pathway.
Inactivation of CD152 during Ag Stimulation of Th2 Cells
Up-regulates FasL. Previous data on the expression of Fas
and FasL in Th1 and Th2 cells are controversial, due to the
Figure 4. CD152 blockade enhances AICD in both T cell subsets
independently of IFN-  and IL-2 induction. (A) Effect of CD152 blockade
on IFN-  production in Th1 and Th2 cells. CD4 CD62L  TCRtg/tg
splenocytes were stimulated in the presence and absence of 200  g/ml of
 CD152 or hamster control Fab fragments. Supernatants were collected
on day 6 after stimulation, and the amount of IFN-  was detected using a
sensitive ELISA with a detection limit of  2 pg/ml. (B) The effect of
neutralizing  IL-2 and  IL-2R  antibodies. Polarized Th1 and Th2 cells
were restimulated as described in Fig. 2 A in the presence of 200  g/ml
of neutralizing  CD152 Fab (black bars) or hamster control Fab fragments
(gray bars). Some cultures (white bars) additionally received 20  g/ml of
each  IL-2 and  IL2-R  to inhibit IL-2 signaling. 6 d after secondary
stimulation, cells were stained with annexin-V and PI to determine the
number of viable cells. The data represent one out of three similar exper-
iments. Stainings were also done on days 4 and 5 with similar results (not
depicted). (C) Effect of exogenous IL-2. Th1 and Th2 cells, generated
and restimulated as described in Fig. 2 A, were treated with 50 U/ml of
exogenous IL-2. Black and gray bars show cells incubated with solely
 CD152 Fabs or ham IgG Fabs (200  g/ml), respectively. The data
represent the results from one out of two similar experiments.Pandiyan et al. 837
use of unspecific antibodies, insufficient T cell polarization,
or the use of different Th effector cell clones and cell lines.
Therefore, we analyzed Fas and FasL expression using po-
larized, pure Th1 and Th2 cells upon restimulation with
APCs and Ag, which allowed physiological TCR signaling
in the presence of dynamic B7 expression. In unstimulated
cells, FasL was not detectable and also expression of Fas was
low. Both Th cell populations showed increased surface
expression of Fas and FasL after the onset of secondary
stimulation, but at different densities (Fig. 6 B). Fas was
strongly expressed 8 h after restimulation and steadily de-
clined thereafter. In general, Th1 cells showed a higher
density of Fas molecules per cell compared with Th2 cells
over the entire time course. Serological inactivation of
CD152 enhanced the expression of Fas in both populations
(Fig. 6 B). Also FasL was expressed at lower levels in Th2
cells. Blockade of CD152 during stimulation substantially
increased FasL expression in Th2 cells, whereas it had no
enhancing effect in Th1 cells. Thus, CD152 modulated ex-
pression of Fas in Th1 and Th2 cells, whereas FasL levels
were regulated by CD152 mainly in Th2 cells. Consis-
tently, FasL was also expressed to substantially higher levels
in CD152 /  T cells compared with wild-type cells after
restimulation with APCs and  CD3 (Fig. 6 C). Therefore,
these results suggest that down-regulation of FasL expres-
sion in Th2 cells might contribute to CD152-mediated re-
sistance against AICD.
CD152-induced Resistance to Apoptosis Is Dependent on PI3
Kinase. CD152 binds to and activates PI3 K and, there-
fore, we examined whether PI3 K was necessary for apop-
tosis resistance induced by CD152. Th2 cells were stimu-
lated for 48 h with plate-bound  CD3 and  CD28, before
CD152 was cross-linked together with  CD3 and  CD28
coupled to microspheres. Because inhibition of PI3  K
might prevent IL-2 production (41) and replating could
cause growth factor deprivation leading to cell death, cells
were supplied with 50 U/ml of exogenous IL-2. When
cells were treated with the PI3 K inhibitors LY294002 or
wortmannin, inhibition of PI3 K activity completely pre-
vented the survival effect of CD152 ligation. The survival
effect of CD152 ligation was attenuated by Ly294002 also
in the absence of IL-2 addition (unpublished data). Thus, T
cells restimulated with  CD3/ CD28 plus  CD152 in the
presence of the PI3 K inhibitors revealed similar frequen-
cies of nonapoptotic cells as T cells stimulated with only
 CD3/ CD28 (Fig. 7 A). The inhibitors themselves were
not cytotoxic as determined by incubation of nonstimu-
lated T cells for 2 d (Fig. 7 A, inset). Also, LY294002 did
not affect the increased cell death induced by neutralizing
 CD152, but only reduced the number of viable Th2 cells
in control cultures, where CD152 signaling was still func-
tional (Fig. 7 B).
PI3 K–mediated generation of the second messenger PIP3
leads to activation of the survival kinase Akt (42). Akt phos-
phorylates and thereby inhibits several proapoptotic factors,
including the Forkhead transcription factor FKHRL1,
which is involved in transactivation of the FasL promoter
(43) and, therefore, might also contribute to CD152-medi-
ated down-regulation of FasL. Therefore, phosphorylated
and inactivated FKHRL1 was analyzed in Ag-primed Th2
cells using a phosphorylation-specific Ab. Unstimulated cells
revealed only low amounts of phosphorylated FKHRL1,
whereas restimulation of Th2 cells resulted in a strong in-
crease of FKHRL1 phosphorylation (Fig. 7 C, left). Most
importantly, when cells were restimulated and CD152 was
blocked by  CD152 Fab, a significant decrease of FKHRL1
phosphorylation was observed. The specificity of the analy-
sis was verified by competition with FKHRL1 peptide as
well as by experiments in the presence of LY294002, both
of which resulted in disappearance of the phosphospecific
protein band (Fig. 7 C, right).
Another consequence of PI3 K–triggered Akt activation
is induction of Bcl-2 expression, which was recently ob-
served in  CD3-stimulated T cells (44). Inhibition of
CD152 strongly reduced the amounts of Bcl-2 in activated
Th2 cells upon restimulation with Ag and APCs, which
was evident in particular on day 1 after restimulation (Fig. 8
A). In addition, experiments with CD152 cross-linking
Figure 5. Cross-linking of CD152 on Th2 cells in-
hibits AICD independently of cell cycle arrest.
CD4 CD62L  TCRtg/tg T cells were stimulated with
OVA323–339 and T cell–depleted splenocytes under Th2
conditions. On day 2 after Ag-specific restimulation,
CFSE-labeled CD4 cells were replated either with
microspheres coated with  CD3,   CD28, and
hamIgG (left) or with microspheres coated with  CD3
and  CD28 plus  CD152 (right). Cells were cultured
in the presence or absence of either dB-cAMP or
L-mimosine, which induced a G1 arrest. On day 3 after
restimulation with the respective antibodies coupled to
microspheres, annexin-V/PI stainings were performed,
and the number of nonapoptotic cells was determined.
An annexin-V staining control performed in the presence
of EGTA is shown (left). The data represent results
from two experiments with similar results.CD152 Signaling Induces Resistance to Apoptosis 838
were performed. In primary Th2 cells as well as in Th2
cells preactivated for 48 h and restimulated with  CD3/
 CD28-coupled microspheres, CD152 activation resulted
in increased Bcl-2 expression (Fig. 8 B). The induction of
Bcl-2 expression by CD152 was completely reversed by
LY294002. Thus, Bcl-2 expression was regulated by
CD152-mediated PI3 K activity during CD3/CD28 stim-
ulation on primary activated Th2 cells. Altogether, our data
show that CD152 is predominantly expressed on activated
Th2 cells and contributes to enhanced resistance of acti-
vated Th2 cells against AICD by down-regulating Fas/FasL
expression, an event closely associated with CD152/PI3
K–mediated up-regulation of Bcl-2.
Discussion
Our results identify enhanced CD152 surface expression
and signaling in Th2 cells as an important functional differ-
ence between Th1 and Th2 cells. CD152 cross-linking in
the Th2 population revealed that a fraction of cells was res-
cued from apoptosis corresponding to the number of Th2
cells expressing surface CD152. The heterogeneity of
CD152 expression in individual primary T cells has not
been analyzed thus far. Our paper shows clearly that Th1
and Th2 cells differ in the frequency of CD152 expression
and, therefore, are remarkably different in their susceptibil-
ity to AICD. Although more Th1 effectors than Th2 cells
underwent Fas/FasL-mediated AICD, mainly Th2 effectors
Figure 6. Fas/FasL interaction is involved in the apoptosis-sensitizing effect of CD152 inhibition. (A) FasL-neutralizing antibodies protect against cell
death induced by  CD152 Fab fragments. Polarized Th1 and Th2 cells were restimulated as described in Fig. 2 A with or without blocking of CD152.
Control ham IgG Fabs and  CD152 Fabs were used at 200  g/ml in primary and secondary stimulations. FasL signaling was blocked during secondary
Ag-specific stimulation by using the neutralizing  murine FasL moAb 3C82 (20  g/ml). After 6 d of secondary stimulation, cell viability was assessed by
annexin-V and PI staining. Data from one out of three similar experiments are shown. Measurements were also performed on day 5 with similar results
(not depicted). (B) Blockade of CD152 up-regulates Fas and FasL expression. Fas and FasL molecules were stained on the surface of Th1 and Th2 cells at
different time points after secondary stimulation with or without blocking of CD152. All stainings were controlled using isotype-matched control anti-
bodies (dotted lines). The histograms from one out of three similar experiments are shown. Geometric means of fluorescence intensity are indicated in
parentheses. (C) FasL is up-regulated in activated CD152 /  T cells. Stainings were performed on CD4  cells from CD152 /  or CD152 /  mice at the
indicated time points after the onset of the secondary stimulation. Dotted gray lines show stainings with isotype-matched control antibodies. Geometric
means of FasL expression in CD152 /  and WT T cells are indicated in parentheses.Pandiyan et al. 839
Figure 7. CD152-mediated inhibition of apoptosis requires a functional PI3 K pathway. (A) Inhibition of PI3 K prevents the protecting effect triggered
by CD152. Th2 cells were generated as described in Fig. 2 A, and on day 2 after secondary stimulation, they were replated with  CD3/ CD28/IgG- or
 CD3/ CD28/ CD152-coated microspheres in the presence or absence of the PI3 K inhibitors wortmannin or LY294002. 4 d after replating cell viability
was determined by annexin-V/PI staining. The inset in A shows a toxicity control in which unstimulated cells were treated with the PI3 K inhibitors for 2 d.
(B) Polarized Th2 cells were restimulated as described in Fig. 2 A with or without blocking of CD152. To inhibit PI3 K, cultures were incubated with
LY294002 during secondary stimulation. After 6 d of secondary stimulation, cell viability was assessed by annexin-V/PI staining. (C) Inhibition of CD152
signaling impairs Ag/APC-induced phosphorylation of Forkhead transcription factor FKHRL1 (left). Th2 cells were generated and restimulated as afore-
mentioned. After 24 h, FKHRL1 phosphorylation was determined in whole cell lysates by immunoblotting using a phosphorylation-specific FKHRL1 Ab.
The FKHRL1-specific protein band is indicated by an arrow, and the asterisks denote a nonspecific protein band that served as a control for equal protein
loading. Additional controls, including incubation of cells in the presence of LY294002 or competition of the Ab with the immunizing FKHRL1 peptide
confirmed the specificity of the immunoblot analysis (right). The data shown represent one out of two to four experiments.
Figure 8. Inhibition of CD152 signaling in Th2 cells down-regulates
Bcl-2 expression. (A) Th2 cells were generated and restimulated as de-
scribed in Fig. 2 A. At the indicated days after the onset of Ag-specific
secondary stimulation, Th2 cells were fixed and stained for Bcl-2 (solid
lines). The geometric means of Bcl-2 expression are indicated in paren-
theses. The dotted lines show the staining obtained with an isotype-
matched control Ab. (B) CD152 ligation up-regulates Bcl-2 expression
by a PI3 K–dependent pathway. Th2 cells were restimulated and treated
in the presence or absence of LY294002 as described in Fig. 7. On day 6
after replating, cells were fixed and stained with Bcl-2–specific (solid
lines) or isotype-matched control antibodies (dotted lines). The percent-
age of cells with up-regulated Bcl-2 expression is indicated. The data
shown represent one out of two to four experiments.
could escape this fate through CD152 engagement. We
demonstrate that antiapoptotic consequences of CD152 li-
gation are associated with up-regulation of Bcl-2, phos-
phorylation of FKHRL1, and reduced Fas/FasL expression.
Expression of CD152 on the surface of primary T cells is
difficult to detect using conventional cytometric and mi-
croscopic techniques (14). Studies on CD152 expression
have been generally performed intracellularly without dis-
criminating CD152 surface expression, and mostly in Th1
and Th2 cell clones or cell lines. The sensitive liposome-
based staining technique used in this work allowed the de-
tection of as few as 100–200 surface molecules per cell. We
show through CD152-specific liposome staining that only
a fraction of primary cells, activated in an appropriate Th1
or Th2 milieu, express surface CD152. The induction of
CD152 expression was rather similar during primary re-
sponses of naive T cells activated under Th1 or Th2 condi-
tions. However, upon secondary stimulation a pronounced
increase of surface CD152-expressing cells was consistently
found in particular in the Th2 population. Hence, the dif-
ferentiation history of an activated naive T cell apparently
correlates with CD152 surface expression upon reencoun-
tering an Ag. The fact that activated Th1 and Th2 cells dif-
ferentially express CD152 during an immune response was
reflected by a functional analysis as follows. When CD152
was ligated at the time point of maximal expression after
the onset of T cell activation, a substantial fraction of the
Th2 cells remained viable.CD152 Signaling Induces Resistance to Apoptosis 840
Our paper is the first demonstrating that CD152 ligation
and genetic or serological ablation of CD152 signaling af-
fects AICD in different primary T cell subsets. At first
view, our data would concur with the observation that
transfection of CD152 could inhibit apoptosis in a T cell
hybridoma cell line (45). However, in this work, the hy-
bridoma cells were not preactivated before CD152 ligation.
As CD152 cross-linking at the beginning of stimulation
leads to a general shutdown of T cell activation associated
with impaired up-regulation of activation molecules, in-
ducible FasL expression will be also abolished. Thus, it is
very likely that in the reported experiments, T cell activa-
tion and not AICD was inhibited by CD152.
AICD of already activated T cells is mainly mediated by
the expression of Fas/FasL. We provide several lines of ev-
idence that CD152 affects AICD mainly by impinging on
the Fas pathway. First, sensitization of activated T cells to
AICD induced by blockade of CD152 was completely
abolished by FasL antibodies. Second, CD152 ligation led
to a strong inhibition of FasL in Th2 cells, whereas de-
creased Fas expression was seen in both effector cell popu-
lations. The inhibition of Fas/FasL expression and a conse-
quently reduced AICD were observed at various time
points after antigenic restimulation, suggesting that CD152
did not simply delay the induction of Fas and FasL expres-
sion. In accordance with this concept is our finding that
FasL was also strongly up-regulated during the onset of ac-
tivation in CD152 /  T cells. It might be argued that up-
regulation of Fas/FasL in CD152 /  T cells is discrepant to
the lymphoproliferative disease observed in CD152 / 
mice. However, CD152 deficiency also strongly affects cell
cycle control and proliferative events that might overcome
the up-regulation of proapoptotic mediators. Thus, experi-
ments with CD152 /  cells, which might be already in ac-
tivated state ex vivo, must certainly be interpreted with
caution. Data with Rag2 /  CD152 /  T cells suggested
that CD152, even though being involved in tolerance in-
duction, does not affect AICD (46). Whether these differ-
ences to our results are caused by differences in the activa-
tion history of cells, effects of CD152 on cell cycle
progression or different experimental systems remains to be
investigated. Nevertheless, and more in line with the
present results, it has been shown that Rag2 /  mice re-
constituted with a mixture of CD152 /  and CD152 /  T
cells do not show enhanced, but even reduced total num-
bers of lymphocytes after infection with LCMV and Leish-
mania major (47). This surprising observation does not only
indicate that CD152 affects T cell survival in a nonautono-
mous fashion but eventually also via modulating the ex-
pression of a proapoptotic factor (47).
Our results identified PI3 K as the presumably crucial
mediator of CD152–induced resistance against AICD. It
has been demonstrated that Akt, a target of PI3 K, is an es-
sential signaling intermediate in this antiapoptotic pathway.
We show that cross-linking of CD152 during T cell activa-
tion induces Bcl-2, which might contribute to the early
protection of T cells. PI3 K, either directly or through the
Akt pathway, is involved in the up-regulation of Bcl-2 after
CD152 ligation. The PI3 K/Akt survival pathway has been
recently reported to be required for the up-regulation of
Bcl-2 by IL-2 (45). As CD152 inhibits IL-2 transcription
during T cell activation, and Bcl-2 is up-regulated by IL-2,
this effect is probably independent of IL-2 and directly due
to CD152 signaling. PI3 K/Akt also inhibits the Forkhead
factor FKHRL1 involved in FasL transcriptional regulation.
Akt phosphorylates FKHRL1 leading to its retention in the
cytoplasm (42). Our results demonstrate that antigenic re-
stimulation of Th2 cells results in phosphorylation of
FKHRL1, which was significantly impaired when CD152
signaling was blocked by  CD152 Fab. The dephosphory-
lation of FKHRL1 induced by CD152 inhibition should
promote nuclear translocation and activation of target
genes such as FasL. It is interesting to note that suppression
of Akt has been recently found to induce FasL expression
in smooth muscle cells (48).
In most analyses, only suppressive functions and down-
regulation of gene expression have been described for
CD152. Apart from TGF , whose role in CD152 function
is obscure, our data show for the first time that CD152 en-
gagement is able to directly induce protein expression (e.g.,
of Bcl-2). The reason why most studies missed such an effect
lies presumably in the fact that CD152 function has been
generally examined after CD152 cross-linking at the onset of
T cell responses, which will fully prevent T cell activation.
Our results suggest that when CD152 is maximally expressed
at the cell surface, CD152 might have more complex func-
tions and actively determines a T effector cell’s fate.
According to our data, T cells would be activated and
primed to die unless they up-regulate surface CD152,
which blocks AICD. As only a fraction of cells up-regulate
surface CD152, and a similar fraction of cells responds to
CD152 cross-linking, we assume that only those cells that
express sufficient surface CD152 and receive appropriate
additional signals will become resistant of apoptosis. That
this restricted population being maintained after the T cell
response fades away might be important to create the
memory for the adaptive immune response. Although Bcl-2,
a T cell memory marker (49, 50), is up-regulated by
CD152 in a fraction of CD4 cells, future studies are needed
to clarify the fate of them and their role in contribution to
the memory cell compartment.
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